查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2029264

多發性硬化症（MS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Multiple Sclerosis (MS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 154 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 美國多發性硬化症市場預計將從 86 億美元成長到 185 億美元，反映出強勁且持續的成長。
  • 以下因素正在推動市場成長：
  • 昂貴的生物製藥和標靶治療（例如抗CD20藥物）的使用日益增多
  • 擴大符合治療條件的患者人數和早期療育策略
  • 市場規模得益於慢性病和終身治療以及疾病修正治療(DMT) 的高昂價格。
  • 針對髓鞘再生和神經保護的新一代療法擁有強大的研發管線。
  • 未來的成長取決於能夠解決進行性多發性硬化症 (MS) 並預防長期殘疾的創新。

多發性硬化症（MS）概述

多發性硬化症（MS）是一種慢性、免疫介導的去髓鞘化神經退化性疾病，主要影響中樞神經系統（CNS），其病因是自體反應性T細胞和B細胞穿過功能異常的血腦障壁。這種免疫介導的攻擊會導致局部發炎、髓鞘破壞、軸突損傷和進行性神經退化，最終在大腦和脊髓中形成特徵性的硬化斑塊。

這種疾病主要發生於青年人，臨床表現為反覆出現的神經功能缺損，例如視神經炎、運動和感覺障礙、協調障礙以及嚴重疲勞。疾病進展可呈現多種模式，包括復發緩解型和進行型，其特徵是症狀在時間和空間上逐漸擴散。

診斷依據麥克唐納標準，該標準整合了 MRI 檢查觀察（例如，腦室周圍病變如道森指）和腦脊髓液 (CSF) 分析結果，顯示寡克隆區帶。

治療方法正朝著積極且有效率的治療方向發展，強調早期啟動疾病修正治療（DMT）以防止不可逆損傷。目前的標準治療方案優先採用標靶治療，例如抗CD20單株抗體（如Ocrelizumab）、S1P受體調變器和整合素抑制劑，這些藥物能有效抑制神經發炎並降低復發率。

儘管治療方法取得了進展，但在解決疾病進行性、治療抗藥性、長期安全性和與發炎無關的神經退化方面仍然存在挑戰，這凸顯了多發性硬化症治療方面仍然存在未滿足的需求。

主要亮點

  • 在美國，確診的多發性硬化症病例數預計將從 717,716 例增加到 737,991 例，這表明該疾病的負擔正在穩步上升。
  • 多發性硬化症主要影響年輕人，並可能導致長期殘疾和嚴重的社會經濟後果。
  • 治療模式正在向早期使用高效的疾病修飾療法來減緩疾病進展的方向轉變。
  • 除了抑制發炎之外，在進行進行性多發性硬化症和神經退化方面仍然存在未滿足的需求。
  • 人們對標靶 B 細胞的治療方法和先進的免疫調節策略越來越感興趣。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Hoffmann-La Roche
  • TG Therapeutics, Inc.
  • Biogen
  • Tr1X, Inc.
  • Sanofi
  • Biocad
  • Kite, A Gilead Company
  • Zenas BioPharma（USA）, LLC
  • Novartis Pharmaceuticals
  • AstraZeneca
  • Truway Health, Inc.
  • Miltenyi Biomedicine GmbH
  • Autolus Limited
  • Qilu Pharmaceutical（Hainan）Co., Ltd.
  • Vidya Therapeutics Inc
  • Genentech, Inc.
  • Cabaletta Bio
  • NeuroGenesis Ltd.
  • Tiziana Life Sciences LTD
  • Sandoz
  • Celgene
  • ModernaTX, Inc.
  • Amgen
  • Contineum Therapeutics
  • Abata Therapeutics
  • Cellerys AG
  • Bristol-Myers Squibb
  • Kyverna Therapeutics
  • Reveal Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
  • Motric Bio
  • LAPIX Therapeutics Inc.
  • Inventage Lab., Inc.
  • Ever Supreme Bio Technology Co., Ltd.
  • AB Science
  • Ashvattha Therapeutics, Inc.
  • Immunic AG
  • GlaxoSmithKline
  • ImStem Biotechnology
  • Anokion SA
  • Clene Nanomedicine
  • Actelion
  • Genzyme, a Sanofi Company

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及關鍵意見領袖的見解
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法—概述、市場上市預期以及關鍵意見領袖 (KOL) 的見解。
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Multiple Sclerosis (MS) Market Outlook

Thelansis's "Multiple Sclerosis (MS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple Sclerosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Multiple Sclerosis (MS) Overview

Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating, and neurodegenerative disorder of the central nervous system (CNS), driven by autoreactive T- and B-cell infiltration across a compromised blood-brain barrier. This immune-mediated attack leads to focal inflammation, myelin destruction, axonal injury, and progressive neurodegeneration, resulting in the formation of characteristic sclerotic plaques across the brain and spinal cord.

The disease predominantly affects young adults, with clinical presentation marked by episodic neurological deficits such as optic neuritis, motor and sensory impairment, coordination dysfunction, and severe fatigue. Disease progression follows patterns including relapsing-remitting and progressive forms, characterized by dissemination in space and time.

Diagnosis is based on the McDonald criteria, integrating MRI findings (e.g., periventricular lesions such as Dawson's fingers) and cerebrospinal fluid analysis showing oligoclonal bands.

Management has evolved toward a proactive, high-efficacy treatment approach, emphasizing early initiation of disease-modifying therapies (DMTs) to prevent irreversible disability. Current standards prioritize targeted therapies, including anti-CD20 monoclonal antibodies (e.g., ocrelizumab), S1P receptor modulators, and integrin inhibitors, which effectively suppress neuroinflammation and reduce relapse rates.

Despite therapeutic advances, challenges remain in addressing progressive disease, treatment resistance, long-term safety, and neurodegeneration independent of inflammation, highlighting ongoing unmet need in MS management.

Key Highlights

  • In the United States, diagnosed MS cases are projected to increase from 717,716 to 737,991, indicating steady growth in disease burden.
  • MS predominantly affects young adults, leading to long-term disability and significant socioeconomic impact.
  • Treatment paradigm has shifted toward early use of high-efficacy DMTs to delay disease progression.
  • Persistent unmet need exists in progressive MS and neurodegeneration beyond inflammation control.
  • Increasing focus on B-cell targeted therapies and advanced immunomodulation strategies.

Market Overview

  • The United States MS market is projected to grow from $8.6B to $18.5B, reflecting strong and sustained expansion.
  • Market growth is driven by:
  • Increased adoption of high-cost biologics and targeted therapies (e.g., anti-CD20 agents)
  • Expansion of treated patient population and early intervention strategies
  • Market value is supported by chronic, lifelong treatment and premium pricing of DMTs.
  • Strong pipeline of next-generation therapies targeting remyelination and neuroprotection.
  • Future growth will depend on innovations addressing progressive MS and long-term disability prevention.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Hoffmann-La Roche
  • TG Therapeutics, Inc.
  • Biogen
  • Tr1X, Inc.
  • Sanofi
  • Biocad
  • Kite, A Gilead Company
  • Zenas BioPharma (USA), LLC
  • Novartis Pharmaceuticals
  • AstraZeneca
  • Truway Health, Inc.
  • Miltenyi Biomedicine GmbH
  • Autolus Limited
  • Qilu Pharmaceutical (Hainan) Co., Ltd.
  • Vidya Therapeutics Inc
  • Genentech, Inc.
  • Cabaletta Bio
  • NeuroGenesis Ltd.
  • Tiziana Life Sciences LTD
  • Sandoz
  • Celgene
  • ModernaTX, Inc.
  • Amgen
  • Contineum Therapeutics
  • Abata Therapeutics
  • Cellerys AG
  • Bristol-Myers Squibb
  • Kyverna Therapeutics
  • Reveal Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
  • Motric Bio
  • LAPIX Therapeutics Inc.
  • Inventage Lab., Inc.
  • Ever Supreme Bio Technology Co., Ltd.
  • AB Science
  • Ashvattha Therapeutics, Inc.
  • Immunic AG
  • GlaxoSmithKline
  • ImStem Biotechnology
  • Anokion SA
  • Clene Nanomedicine
  • Actelion
  • Genzyme, a Sanofi Company

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)